Immunogenicity and Safety Study of GSK Biologicals' Cell Culture Derived Pandemic Influenza Vaccines GSK2590066A and GSK2340273A Administered to Healthy Adults 18 - 49 Years Old
Phase of Trial: Phase I
Latest Information Update: 12 May 2017
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary) ; Influenza A virus vaccine-H1N1
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 22 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Aug 2011 Planned end date changed from 1 Aug 2012 to 1 Sep 2011 as reported by ClinicalTrials.gov.
- 04 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.